Protein Expression

Protein Expression

Identification & Validation

Information

Wheeler Bio provides high-quality transient protein expression services for drug developers, enabling them to swiftly produce and characterize their product candidates, thereby accelerating time to final candidate selection. Our dedicated protein sciences team – based in Waltham, MA and Oklahoma City – utilizes vast experience in protein design and expression to design experiments that will meet your needs in generating and characterizing multiple constructs for final candidate selection. Leveraging our team’s extensive expertise and proprietary technologies, we ensure efficient and optimal results through CHO- and HEK-based transient protein expression and the utilization of cutting-edge systems like Expi293 and Leap-In Transposase technology for the rapid generation of milligram to gram quantities of stable recombinant proteins. This material is then used for rapid and cost-effective molecular format screening and vector engineering to enhance the final candidate, making Wheeler’s platform particularly advantageous for early-stage drug developers looking to maximize their resources while on a tight timeline to proof-of-concept studies.
Wheeler Bio832Wheeler Bio is a biomanufacturing pioneer founded by a team of industry experts and strategic investors who believe a different CDMO model is needed for innovators to bring new therapeutic leads to the clinic faster, without the risk and cost associated with traditional outsourcing models. Our novel hub-and-spoke concept, centered in Oklahoma City with satellite labs embedded in discovery centers on the coasts, will revolutionize the translational path from discovery to CMC development and first patient dosing. Wheeler’s pioneering, highly-accessible, open-source development platform – Portable CMC® – delivers speed to clinic and uniquely-affordable workflows by integrating discovery CROs and CDMOs. Portable CMC® is a suite-ready drug substance manufacturing platform that customers can transfer to any CDMO in the world with no royalties, licensing fees or penalties. By overlapping with the discovery workflow, Portable CMC® reduces timelines and regulatory risks through the introduction of QbD (Quality-by-Design) principles earlier on in the drug development life cycle, increasing the opportunity for clinical success.

Log in